Tech Company Financing Transactions
Khartis Therapeutics Funding Round
Khartis Therapeutics, based in San Diego, secured $50 million in investment from Forge Life Science Partners, Alexandria Venture Investments and Foresite Capital.
Transaction Overview
Company Name
Announced On
8/13/2026
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the advancement of its lead program, an oral selective IGF-1R inhibitor designed for the treatment of thyroid eye disease (TED), as well as the continued development of its broader pipeline of oral small molecule medicines targeting clinically validated immunology pathways.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3911 Sorrento Valley Blvd 130
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Khartis is a biotechnology company developing first- and best-in-class oral small molecule medicines targeting clinically validated immunology pathways. The company's lead program is the first oral, selective IGF-1R inhibitor designed for the treatment of thyroid eye disease (TED).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Chris LeMasters
Chief Executive Officer
Robert Hoffman
Chief Scientific Officer
Craig Murphy
Browse more venture capital transactions:
Prev: 8/13/2026: Wippi venture capital transaction
Next: 8/13/2026: Databricks venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs